STOCK TITAN
  1. Home
  2. Sec-filings
  3. CCCC
  4. [SCHEDULE 13G/A] C4 Therapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] C4 Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CCCC logo
C4 Therapeutics, Inc.

NASDAQ:CCCC

CCCC Rankings

#4254 Ranked by Market Cap
N/A Ranked by Dividends

CCCC Latest News

Sep 3, 2025
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
Aug 7, 2025
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
May 7, 2025
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Feb 27, 2025
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Feb 24, 2025
C4 Therapeutics to Participate in Upcoming March Investor Conferences

CCCC Latest SEC Filings

Aug 7, 2025
[SCHEDULE 13G/A] C4 Therapeutics, Inc. SEC Filing
Aug 7, 2025
[10-Q] C4 Therapeutics, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] C4 Therapeutics, Inc. Reports Material Event
Jul 15, 2025
[Form 4/A] C4 Therapeutics, Inc. Amended Insider Trading Activity
Jul 14, 2025
[Form 4] C4 Therapeutics, Inc. Insider Trading Activity

CCCC Stock Data

185.04M
57.13M
9.75%
76.91%
6.54%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WATERTOWN